Serono Genetics Institute S.a.

Barbara A Chicca

Bernard Bihain

Hiroaki Tanaka

Mary Erickson

Jean-Baptiste Dumas Milne Edwards

Frances Yen-Potin

Stephane Bejanin

Severin Jobert

Jean-Yves Giordano

Deno Dialynas

Blake Denison

Tom Chu

Aaron Scalia

John Chicca

The present invention relates to the field of metabolic research. Metabolic disorders, such as obesity, are a public health problem that is serious and widespread. GMG-3, GMG-4, Cluster 1, GMG-6A, or GMG-6B polypeptides have been identified that are beneficial in the treatment of metabolic disorders. These compounds should be effective for reducing body mass and for treating metabolic-related diseases and disorders. These metabolic-related diseases and disorders include hyperlipidemias, atherosclerosis, diabetes, and hypertension.

Metabolic gene polynucleotides and polypeptides and uses thereof

GMG-3 GMG-4 and GMG-6 polynucleotides and polypeptides and uses thereof

The present invention relates to the field of metabolic research. Metabolic disorders, such as obesity, are a public health problem that is serious and widespread. GSSP4 polypeptides have been identified that are believed to be beneficial in the treatment of metabolic disorders. These compounds should be effective for reducing cholesterol levels, body mass, body fat, and for treating metabolic-related diseases and disorders. The metabolic-related diseases or disorders include, but are not limited to, obesity, hyperlipidemia, hypercholesterolemia, atherosclerosis, diabetes, glucose intolerance, insulin resistance and hypertension.

GSSP4 polynucleotides and polypeptides and uses thereof

Growing community of inventors

San Diego, CA, United States of America

Barbara A Chicca